Paper Details

  1. Home
  2. Paper Details

Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.

Author: AbdelmalekMohamed O, Abu-FaddanNagla H, IbrahimMohamed Eltaher, KheilaAbeer E, MahmoudAmal A, MakhloufNahed A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ledipsavir/sofosbuvir was effective in treating chronic hepatitis C virus (HCV) genotype 4 in adolescents with or without hematological disorders, and sustained virological response (SVR) improved liver stiffness.
Paper Details　
Original Abstract of the Article :
Egypt has the highest prevalence of hepatitis C virus (HCV) infection. Anti-HCV antibodies were detectable in 3% of children in Upper Egypt. Our aim was to evaluate the efficacy of ledipasvir/sofosbuvir for chronic HCV genotype 4 in adolescents with/without hematological disorders and to determine t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jpids/piaa006

データ提供：米国国立医学図書館（NLM）

Hepatitis C in Adolescents: Navigating a Desert of Challenges

Hepatitis C virus (HCV) infection presents a significant challenge, particularly in regions like Egypt, where it has a high prevalence. This study examines the efficacy of ledipasvir/sofosbuvir, a direct-acting antiviral agent, in treating chronic HCV genotype 4 in adolescents, both those with and without hematological disorders. Researchers sought to find a safe and effective treatment for this debilitating viral infection, navigating the complexities of adolescent health and hematological conditions.

A New Path to Cure: Ledipsavir/Sofosbuvir Shows Promise

The research, like a skilled desert explorer, found that ledipasvir/sofosbuvir demonstrated high efficacy in treating chronic HCV genotype 4 in adolescents, achieving sustained virological response (SVR) in a significant portion of patients. This study offers hope for adolescents struggling with HCV infection, providing a promising path to a cure.

Fighting the Virus: A Camel's Perspective

The desert of HCV infection can be a perilous journey, but this study offers a glimmer of hope for adolescents. Ledipsavir/sofosbuvir shows promise as an effective treatment, potentially leading to a cure. It's essential to consult with a doctor to determine if this treatment option is right for you based on your individual needs and medical history.

Dr.Camel's Conclusion

This study highlights the efficacy of ledipasvir/sofosbuvir in treating chronic HCV genotype 4 in adolescents, offering a promising treatment option for this challenging viral infection. This finding offers hope for a future free from the burden of HCV, providing a path to a healthier life. Just as a camel adapts to the harsh desert environment, adolescents with HCV can find strength and resilience in the face of this challenge, with effective treatments and dedicated healthcare support.

Date :
  1. Date Completed 2021-02-25
  2. Date Revised 2021-02-25
Further Info :

Pubmed ID

32060510

DOI: Digital Object Identifier

10.1093/jpids/piaa006

Related Literature

Article Analysis
・Side Effects of ledipasvir and sofosbuvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.